MYRF

Summary

MYRF (myelin regulatory factor, HGNC:1181) is a protein-coding gene on chromosome 11q12.2, encoding Myelin regulatory factor (Q9Y2G1). Constitutes a precursor of the transcription factor.

This gene encodes a transcription factor that is required for central nervous system myelination and may regulate oligodendrocyte differentiation. It is thought to act by increasing the expression of genes that effect myelin production but may also directly promote myelin gene expression. Loss of a similar gene in mouse models results in severe demyelination. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 745 — RefSeq curated summary.

At a glance

• Gene–disease (curated): cardiac-urogenital syndrome (Definitive, ClinGen) — +2 more curated relationships
• GWAS associations: 142
• Clinical variants (ClinVar): 363 total — 35 pathogenic, 33 likely-pathogenic
• Phenotypes (HPO): 44
• Transcription factor: yes — 12 downstream targets (CollecTRI)
• MANE Select transcript: NM_001127392

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1181
Approved symbol	MYRF
Name	myelin regulatory factor
Location	11q12.2
Locus type	gene with protein product
Status	Approved
Aliases	Ndt80, pqn-47, MRF
Ensembl gene	ENSG00000124920
Ensembl biotype	protein_coding
OMIM	608329
Entrez	745

Gene structure

Transcript identifiers

Ensembl transcripts: 29 — 21 protein_coding, 6 retained_intron, 2 nonsense_mediated_decay

ENST00000265460, ENST00000278836, ENST00000389602, ENST00000536352, ENST00000537318, ENST00000537766, ENST00000539361, ENST00000546247, ENST00000675319, ENST00000675345, ENST00000675792, ENST00000856798, ENST00000856799, ENST00000856800, ENST00000856801, ENST00000856802, ENST00000856803, ENST00000856804, ENST00000856805, ENST00000856806, ENST00000856807, ENST00000856808, ENST00000856809, ENST00000856810, ENST00000856811, ENST00000856812, ENST00000856813, ENST00000918478, ENST00000918479

RefSeq mRNA: 2 — MANE Select: NM_001127392 NM_001127392, NM_013279

CCDS: CCDS31579, CCDS44622

Canonical transcript exons

ENST00000278836 — 27 exons

Exon	Start	End
ENSE00000851667	61770246	61770525
ENSE00000851668	61769260	61769321
ENSE00000851669	61765958	61766221
ENSE00000916469	61777734	61777845
ENSE00000916471	61777264	61777464
ENSE00000916474	61776787	61776877
ENSE00000916486	61771829	61771952
ENSE00000916488	61771500	61771750
ENSE00001140120	61776322	61776432
ENSE00001196708	61752636	61752790
ENSE00001228603	61783498	61783600
ENSE00001324593	61765625	61765712
ENSE00001357447	61776056	61776132
ENSE00001506342	61773967	61774162
ENSE00001726169	61784280	61784385
ENSE00001757101	61785800	61785874
ENSE00001803334	61783851	61783925
ENSE00001806276	61779263	61779423
ENSE00002268635	61786063	61788518
ENSE00002319261	61778380	61778489
ENSE00003462587	61780712	61780792
ENSE00003502350	61780222	61780290
ENSE00003506782	61781138	61781329
ENSE00003526766	61779498	61779570
ENSE00003529284	61781573	61781824
ENSE00003568414	61779842	61779930
ENSE00003642612	61780960	61781045

Expression profiles

Bgee: expression breadth ubiquitous, 223 present calls, max score 99.20.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 23.4766 / max 1290.5938, expressed in 1002 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
114597	22.8323	1000
114600	0.3329	152
114599	0.1994	54
114601	0.1016	54
114598	0.0103	4

Top tissues by expression

286 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
middle frontal gyrus	UBERON:0002702	99.20	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	98.81	gold quality
inferior vagus X ganglion	UBERON:0005363	98.71	gold quality
spinal cord	UBERON:0002240	98.64	gold quality
inferior olivary complex	UBERON:0002127	98.45	gold quality
medulla oblongata	UBERON:0001896	97.31	gold quality
subthalamic nucleus	UBERON:0001906	97.23	gold quality
ventral tegmental area	UBERON:0002691	96.86	gold quality
lateral globus pallidus	UBERON:0002476	96.80	gold quality
superior vestibular nucleus	UBERON:0007227	96.25	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	96.22	gold quality
dorsal plus ventral thalamus	UBERON:0001897	96.20	gold quality
midbrain	UBERON:0001891	96.19	gold quality
substantia nigra pars reticulata	UBERON:0001966	96.17	gold quality
pigmented layer of retina	UBERON:0001782	96.14	gold quality
substantia nigra	UBERON:0002038	96.09	gold quality
corpus callosum	UBERON:0002336	95.79	gold quality
putamen	UBERON:0001874	95.78	gold quality
pylorus	UBERON:0001166	95.44	gold quality
gall bladder	UBERON:0002110	95.24	gold quality
globus pallidus	UBERON:0001875	94.82	gold quality
cranial nerve II	UBERON:0000941	94.76	gold quality
Ammon’s horn	UBERON:0001954	94.64	gold quality
CA1 field of hippocampus	UBERON:0003881	94.50	gold quality
amygdala	UBERON:0001876	94.27	gold quality
medial globus pallidus	UBERON:0002477	94.20	gold quality
right lung	UBERON:0002167	94.16	gold quality
body of pancreas	UBERON:0001150	94.04	gold quality
caudate nucleus	UBERON:0001873	94.01	gold quality
substantia nigra pars compacta	UBERON:0001965	93.64	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-MTAB-6108	yes	122.62
E-GEOD-84465	yes	12.51
E-ANND-3	yes	4.33

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

12 targets.

Target	Regulation
ABCB1
ADAM2
CDR2
COL5A2
EIF3K
FGF2
MIR499A
MYF6
MYH7B
MYOG
SMARCA4
STAB1

miRNA regulators (miRDB)

142 targeting MYRF, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-4645-5P	99.98	65.81	1284
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-5195-3P	99.92	70.92	1877
HSA-MIR-145-5P	99.92	71.13	1836
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-302A-3P	99.89	71.23	1777
HSA-MIR-302B-3P	99.89	71.23	1777

Literature-anchored findings (GeneRIF, showing 21)

• A Bacteriophage tailspike domain promotes self-cleavage of a human membrane-bound transcription factor, the myelin regulatory factor MYRF. (PMID:23966832)
• molecular mechanisms underlying the homo-trimerization of Myrf N-terminal fragments and the homo-trimeric DNA binding of Myrf N-terminal fragments (PMID:28160598)
• The relative scarcity of oligodendrocyte lineage cells expressing MYRF in demyelinated MS lesions demonstrates, for the first time, that chronic lesions lack oligodendrocytes that express this necessary transcription factor for remyelination and supports the notion that a failure to fully differentiate underlies remyelination failure. (PMID:28631093)
• Functional defects of MYRF are likely to be causally associated with encephalopathy with extensive myelin vacuolization (PMID:29265453)
• Heterozygous variants in MYRF should be considered in patients with variants of Scimitar syndrome and urogenital anomalies. (PMID:29446546)
• We identified four unrelated individuals with congenital diaphragmatic hernia with damaging de novo variants in MYRF (P = 5.3x10(-8)), including one likely gene-disrupting (LGD) and three deleterious missense (D-mis) variants. Eight additional individuals with de novo LGD or missense variants were identified from our other genetic studies or from the literature. (PMID:30532227)
• The results suggest that MYRF is a novel causative gene of 46,XY and 46,XX disorders of sex development and MYRF is a transcription factor regulating coelomic epithelium and/or coelomic epithelium derived cells proliferation and migration, which is essential for development of multiple organs. (PMID:30985895)
• Identified a canonical splice site alteration upstream of the last exon of the gene encoding myelin regulatory factor (MYRF c.3376-1G>A), which produced a stable RNA transcript, leading to a frameshift mutation p.Gly1126Valfs*31 in the C-terminus of the protein. (PMID:31048900)
• results underline the importance of including SLC18A3 sequencing in the differential diagnostics of fetuses with arthrogryposis, FADS, or LMPS of unknown etiology (PMID:31069960)
• These evidence all support that truncation mutations in the C-terminal region of MYRF are responsible for autosomal dominant high hyperopia in these families. (PMID:31172260)
• This is the first trio-based whole-genome sequencing (WGS), study for nanophthalmos, revealing the potential role of de novo mutations (DNMs) in MYRF and rare inherited genetic variants in PRSS56 and MFRP. (PMID:31266062)
• C-terminal variants in MYRF, which are expected to escape nonsense-mediated decay, represent a rare cause of autosomal dominant nanophthalmos with or without dextrocardia or congenital diaphragmatic hernia. (PMID:31700225)
• Functional mechanism and pathogenic potential of MYRF ICA domain mutations implicated in birth defects. (PMID:31964908)
• The genetic and clinical landscape of nanophthalmos and posterior microphthalmos in an Australian cohort. (PMID:32052405)
• Pancreatic Cancer Cells Require the Transcription Factor MYRF to Maintain ER Homeostasis. (PMID:32997974)
• Common Myelin Regulatory Factor Gene Variants Predisposing to Excellence in Sports. (PMID:33670313)
• Functional mechanisms of MYRF DNA-binding domain mutations implicated in birth defects. (PMID:33798553)
• MYRF: A Mysterious Membrane-Bound Transcription Factor Involved in Myelin Development and Human Diseases. (PMID:33864620)
• Evaluation of MYRF as a candidate gene for primary angle closure glaucoma. (PMID:35136345)
• Truncation mutations in MYRF underlie primary angle closure glaucoma. (PMID:36129575)
• Two sisters with cardiac-urogenital syndrome secondary to pathogenic splicing variant in the MYRF gene with unaffected parents: A case of gonadal mosaicism? (PMID:36695166)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	myrf	ENSDARG00000078676
mus_musculus	Myrf	ENSMUSG00000036098
rattus_norvegicus	Myrf	ENSRNOG00000028274
drosophila_melanogaster	CG3328	FBGN0034985
caenorhabditis_elegans		WBGENE00004134
caenorhabditis_elegans		WBGENE00008999

Paralogs (1): MYRFL (ENSG00000166268)

Protein

Protein identifiers

Myelin regulatory factor — Q9Y2G1 (reviewed: Q9Y2G1)

Alternative names: Myelin gene regulatory factor

All UniProt accessions (4): Q9Y2G1, A0A6Q8PFL7, A0A6Q8PFY9, A0A6Q8PHM1

UniProt curated annotations — full annotation on UniProt →

Function. Constitutes a precursor of the transcription factor. Mediates the autocatalytic cleavage that releases the Myelin regulatory factor, N-terminal component that specifically activates transcription of central nervous system (CNS) myelin genes. Membrane-bound part that has no transcription factor activity and remains attached to the endoplasmic reticulum membrane following cleavage. Transcription factor that specifically activates expression of myelin genes such as MBP, MOG, MAG, DUSP15 and PLP1 during oligodendrocyte (OL) maturation, thereby playing a central role in oligodendrocyte maturation and CNS myelination. Specifically recognizes and binds DNA sequence 5’-CTGGYAC-3’ in the regulatory regions of myelin-specific genes and directly activates their expression. Not only required during oligodendrocyte differentiation but is also required on an ongoing basis for the maintenance of expression of myelin genes and for the maintenance of a mature, viable oligodendrocyte phenotype.

Subunit / interactions. Homotrimer. Interacts (via C-terminal region) with TMEM98; the interaction inhibits MYRF self-cleavage.

Subcellular location. Endoplasmic reticulum membrane Nucleus. Cytoplasm Endoplasmic reticulum membrane.

Tissue specificity. Expressed in lung, brainstem, uterus and, to a lesser extent, in basal ganglion and liver. Weakly expressed in cerebellum. High expression detected in the retinal pigment epithelium, choroid, and optic nerve.

Post-translational modifications. Glycosylated. Follows autocatalytic cleavage via the peptidase S74 domain. Autoprocessing is apparently constitutive and is essential for transcriptional activity. Autocatalytic cleavage is inhibited by interaction with TMEM98.

Disease relevance. Encephalitis/encephalopathy, mild, with reversible myelin vacuolization (MMERV) [MIM:618113] An autosomal dominant disease characterized by episodes of acute encephalitis associated with impaired consciousness, delirious behavior, seizures, and reversible splenial lesions observed on diffusion magnetic resonance imaging. Most patients completely recover and there are no neurologic sequelae. MMERV occurs in children and is frequently associated with a trigger, such as a febrile illness. The disease may be caused by variants affecting the gene represented in this entry. Cardiac-urogenital syndrome (CUGS) [MIM:618280] An autosomal dominant syndrome characterized by partial anomalous pulmonary venous return, tracheal anomalies, pulmonary hypoplasia, congenital diaphragmatic hernia, thyroid fibrosis, thymic involution, cleft spleen, penoscrotal hypospadias, and cryptorchidism. The disease is caused by variants affecting the gene represented in this entry. Nanophthalmos 1 (NNO1) [MIM:600165] A form of nanophthalmos, a disorder of eye development characterized by extreme hyperopia and small functional eyes. The cornea and lens are normal in size and shape. Hyperopia occurs because insufficient growth along the visual axis places these lensing components too close to the retina. Nanophthalmic eyes show considerable thickening of both the choroidal vascular bed and scleral coat, which provide nutritive and structural support for the retina. NNO1 inheritance is autosomal dominant. The disease is caused by variants affecting the gene represented in this entry.

Domain organisation. The nuclear localization signals mediate translocation to the nucleus. The peptidase S74 domain, also named Intramolecular Chaperone Auto-processed (ICA) domain or Intramolecular Chaperone Domain (ICD), has protease activity and mediates autocatalytic processing of the protein to generate the Myelin regulatory factor, N-terminal active transcription factor and the Myelin regulatory factor, C-terminal components.

Similarity. Belongs to the MRF family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9Y2G1-1	1	yes
Q9Y2G1-2	2

RefSeq proteins (2): NP_001120864, NP_037411 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR008967	p53-like_TF_DNA-bd_sf	Homologous_superfamily
IPR024061	NDT80_DNA-bd_dom	Domain
IPR025719	MYRF_C2	Domain
IPR026932	MYRF_ICA	Domain
IPR030392	S74_ICA	Domain
IPR037141	NDT80_DNA-bd_dom_sf	Homologous_superfamily
IPR051577	MRF-like	Family

Pfam: PF05224, PF13884, PF13887, PF13888

UniProt features (73 total): strand 18, mutagenesis site 10, sequence variant 9, region of interest 5, compositionally biased region 5, glycosylation site 4, chain 3, splice variant 3, sequence conflict 3, short sequence motif 2, topological domain 2, turn 2, coiled-coil region 1, site 1, modified residue 1, transmembrane region 1, helix 1, domain 1, DNA-binding region 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
5YHU	X-RAY DIFFRACTION	1.85
5ZHU	X-RAY DIFFRACTION	2.2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y2G1-F1	61.76	0.29

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 586–587 (cleavage; by autolysis)

Post-translational modifications (1): 123

Glycosylation sites (4): 919, 1043, 1065, 1129

Mutagenesis-validated functional residues (10):

Position	Phenotype
454	decreased affinity for dna.
478	decreased affinity for dna.
530	decreased affinity for dna.
587	prevents autocatalytic cleavage and generation of myelin regulatory factor, n-terminal part.
588	reduces autocatalytic cleavage and generation of myelin regulatory factor, n-terminal part.
592	prevents autocatalytic cleavage and generation of myelin regulatory factor, n-terminal part.
608	does not affect autocatalytic cleavage.
635	reduces autocatalytic cleavage and generation of myelin regulatory factor, n-terminal part.
688	does not affect autocatalytic cleavage.
699	prevents autocatalytic cleavage and generation of myelin regulatory factor, n-terminal part.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 341 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_DN, RNGTGGGC_UNKNOWN, TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONOCYTE_UP, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_RESPONSE_TO_COCAINE, GOBP_RESPONSE_TO_IMMOBILIZATION_STRESS, TGCACTT_MIR519C_MIR519B_MIR519A, CROONQUIST_NRAS_SIGNALING_DN, ASTON_MAJOR_DEPRESSIVE_DISORDER_DN, GOBP_POSITIVE_REGULATION_OF_GLIAL_CELL_DIFFERENTIATION, GOBP_PLASMA_MEMBRANE_ORGANIZATION, GOBP_GLIAL_CELL_DEVELOPMENT, FRASOR_RESPONSE_TO_SERM_OR_FULVESTRANT_DN, GOBP_NEUROGENESIS, CREBP1_Q2

GO Biological Process (14): oligodendrocyte development (GO:0014003), protein autoprocessing (GO:0016540), central nervous system myelination (GO:0022010), positive regulation of myelination (GO:0031643), central nervous system myelin maintenance (GO:0032286), response to immobilization stress (GO:0035902), response to cocaine (GO:0042220), positive regulation of DNA-templated transcription (GO:0045893), oligodendrocyte differentiation (GO:0048709), positive regulation of oligodendrocyte differentiation (GO:0048714), regulation of DNA-templated transcription (GO:0006355), regulation of transcription by RNA polymerase II (GO:0006357), proteolysis (GO:0006508), cell differentiation (GO:0030154)

GO Molecular Function (7): DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription factor activity (GO:0003700), peptidase activity (GO:0008233), identical protein binding (GO:0042802), sequence-specific DNA binding (GO:0043565), DNA binding (GO:0003677), hydrolase activity (GO:0016787)

GO Cellular Component (9): nucleus (GO:0005634), nucleoplasm (GO:0005654), endoplasmic reticulum membrane (GO:0005789), Golgi apparatus (GO:0005794), cytosol (GO:0005829), cytoplasm (GO:0005737), endoplasmic reticulum (GO:0005783), endomembrane system (GO:0012505), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
regulation of DNA-templated transcription	3
intracellular membrane-bounded organelle	3
cytoplasm	3
oligodendrocyte differentiation	2
myelination	2
DNA-templated transcription	2
endomembrane system	2
glial cell development	1
protein processing	1
oligodendrocyte development	1
axon ensheathment in central nervous system	1
regulation of myelination	1
positive regulation of nervous system process	1
positive regulation of cellular process	1
central nervous system myelination	1
myelin maintenance	1
response to stress	1
response to alkaloid	1
response to oxygen-containing compound	1
positive regulation of RNA biosynthetic process	1
central nervous system development	1
glial cell differentiation	1
positive regulation of glial cell differentiation	1
regulation of oligodendrocyte differentiation	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
transcription by RNA polymerase II	1
protein metabolic process	1
cellular developmental process	1
chromatin	1
RNA polymerase II transcription regulatory region sequence-specific DNA binding	1
DNA-binding transcription factor activity	1
regulation of transcription by RNA polymerase II	1
transcription cis-regulatory region binding	1
transcription regulator activity	1
hydrolase activity	1
catalytic activity, acting on a protein	1
protein binding	1
DNA binding	1

Protein interactions and networks

STRING

930 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MYRF	BEST1	O76090	832
MYRF	SOX10	P56693	787
MYRF	FEN1	P39748	774
MYRF	TMEM98	Q9Y2Y6	757
MYRF	PLP1	P04400	741
MYRF	SPO11	Q9Y5K1	703
MYRF	OLIG1	Q8TAK6	693
MYRF	OLIG2	Q13516	683
MYRF	MBP	P02686	613
MYRF	NKX2-2	O95096	609
MYRF	RFFL	Q8WZ73	597
MYRF	REC8	O95072	578
MYRF	MOBP	Q13875	565
MYRF	FA2H	Q7L5A8	551
MYRF	ENPP6	Q6UWR7	546

IntAct

24 interactions, top by confidence:

A	B	Type	Score
PDGFRB	PIK3R2	psi-mi:“MI:0914”(association)	0.610
GRAMD2B	EFCAB14	psi-mi:“MI:0914”(association)	0.530
CTLA4	B4GALT5	psi-mi:“MI:0914”(association)	0.530
KCNE3	RIOK3	psi-mi:“MI:0914”(association)	0.530
NS3	C15orf61	psi-mi:“MI:0914”(association)	0.350
	SHTN1	psi-mi:“MI:0914”(association)	0.350
	TMEM223	psi-mi:“MI:0914”(association)	0.350
	TNFRSF10A	psi-mi:“MI:0914”(association)	0.350
PCDHB3	ESYT2	psi-mi:“MI:0914”(association)	0.350
KCNE3	TMEM131L	psi-mi:“MI:0914”(association)	0.350
GPRC5B	TNFRSF10A	psi-mi:“MI:0914”(association)	0.350
ACKR3	PDE2A	psi-mi:“MI:0914”(association)	0.350
CHRNB1	CLGN	psi-mi:“MI:0914”(association)	0.350
DLK1	PLPP3	psi-mi:“MI:0914”(association)	0.350
FYN	MYCBP2	psi-mi:“MI:0914”(association)	0.350
MICB	LGALS8	psi-mi:“MI:0914”(association)	0.350
OSTM1	ASMTL	psi-mi:“MI:0914”(association)	0.350
PCDHGA5	UPK3BL1	psi-mi:“MI:0914”(association)	0.350
PRMT2	DIAPH2	psi-mi:“MI:0914”(association)	0.350
TMEM98	PDGFRB	psi-mi:“MI:0914”(association)	0.350
TNFSF13	FADS1	psi-mi:“MI:0914”(association)	0.350
ZDHHC11	NRP1	psi-mi:“MI:0914”(association)	0.350

BioGRID (25): MYRF (Proximity Label-MS), MYRF (Affinity Capture-MS), MYRF (Affinity Capture-MS), MYRF (Affinity Capture-MS), MYRF (Affinity Capture-MS), MYRF (Affinity Capture-MS), MYRF (Proximity Label-MS), MYRF (Proximity Label-MS), MYRF (Proximity Label-MS), MYRF (Proximity Label-MS), MYRF (Proximity Label-MS), MYRF (Proximity Label-MS), MYRF (Proximity Label-MS), MYRF (Proximity Label-MS), MYRF (Affinity Capture-MS)

ESM2 similar proteins: A1YFY6, A2T6X9, A6H7I8, B2RUJ5, F1M5F3, F1N2W9, O35430, O35431, O95487, O95628, O95644, P0C6S7, P14316, P17863, P22681, P22682, P23798, P23906, P35227, P81133, P98084, Q02410, Q0IHY4, Q13469, Q14190, Q14432, Q1L994, Q3UR85, Q52L14, Q5CD77, Q5RD33, Q60591, Q61045, Q61079, Q66JB6, Q69ZT9, Q6NRE7, Q6QB00, Q8BIZ1, Q8BT14

Diamond homologs: D9PTN5, G5EFI7, Q1ZXA9, Q3UN70, Q3UR85, Q54B29, Q66IV1, Q9Y2G1, F1N4M2, Q54PT9, Q96LU7, B0FIH7

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
MAP2K1	“down-regulates activity”	MYRF	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

363 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	35
Likely pathogenic	33
Uncertain significance	186
Likely benign	43
Benign	31

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1013323	NM_001127392.3(MYRF):c.1705G>T (p.Glu569Ter)	Pathogenic
1176284	NM_001127392.3(MYRF):c.350del (p.Gly117fs)	Pathogenic
1180013	NM_001127392.3(MYRF):c.1072C>T (p.Gln358Ter)	Pathogenic
1698932	NM_001127392.3(MYRF):c.648C>A (p.Tyr216Ter)	Pathogenic
1710281	NM_001127392.3(MYRF):c.428del (p.Gly143fs)	Pathogenic
2307379	NM_001127392.3(MYRF):c.1207C>T (p.Gln403Ter)	Pathogenic
2441925	NM_001127392.3(MYRF):c.1543C>T (p.Gln515Ter)	Pathogenic
2582895	NM_001127392.3(MYRF):c.871C>T (p.Arg291Ter)	Pathogenic
2584483	NM_001127392.3(MYRF):c.2956C>T (p.Arg986Ter)	Pathogenic
2633042	NM_001127392.3(MYRF):c.492_493del (p.Glu164fs)	Pathogenic
3030545	NM_001127392.3(MYRF):c.1208A>T (p.Gln403Leu)	Pathogenic
3235908	NM_001127392.3(MYRF):c.135-119_1062del	Pathogenic
3346708	NM_001127392.3(MYRF):c.1948A>T (p.Lys650Ter)	Pathogenic
3772320	NM_001127392.3(MYRF):c.148_152del (p.Ile50fs)	Pathogenic
3777343	NM_001127392.3(MYRF):c.1116-3C>G	Pathogenic
3894587	NM_001127392.3(MYRF):c.3376-1G>A	Pathogenic
3894588	MYRF, 1-BP DUP, 769C	Pathogenic
3894589	MYRF, 1-BP DEL, 789C (rs769274302)	Pathogenic
3894590	MYRF, 1-BP DUP, 789C (rs769274302)	Pathogenic
3894591	MYRF, ARG478PRO	Pathogenic
3894592	MYRF, ARG986TER	Pathogenic
4072342	NM_001127392.3(MYRF):c.3091del (p.Gln1031fs)	Pathogenic
4536237	NM_001127392.3(MYRF):c.278del (p.Pro93fs)	Pathogenic
4537406	NM_001127392.3(MYRF):c.1134_1135del (p.Val379fs)	Pathogenic
560883	NM_001127392.3(MYRF):c.1208A>G (p.Gln403Arg)	Pathogenic
599372	NM_001127392.3(MYRF):c.2518C>T (p.Arg840Ter)	Pathogenic
599373	NM_001127392.3(MYRF):c.1254_1255dup (p.Thr419fs)	Pathogenic
620313	NM_001127392.3(MYRF):c.2817G>A (p.Trp939Ter)	Pathogenic
635185	NM_001127392.3(MYRF):c.3361del (p.Arg1121fs)	Pathogenic
635274	NM_001127392.3(MYRF):c.3118A>G (p.Arg1040Gly)	Pathogenic

SpliceAI

5119 predictions. Top by Δscore:

Variant	Effect	Δscore
11:61765620:TGCA:T	acceptor_loss	1.0000
11:61765622:CAGGC:C	acceptor_loss	1.0000
11:61765623:A:AG	acceptor_gain	1.0000
11:61765624:G:GA	acceptor_gain	1.0000
11:61765624:GGC:G	acceptor_gain	1.0000
11:61765624:GGCC:G	acceptor_gain	1.0000
11:61765696:G:GT	donor_gain	1.0000
11:61765699:G:GT	donor_gain	1.0000
11:61765708:GACCT:G	donor_gain	1.0000
11:61765709:ACCT:A	donor_gain	1.0000
11:61765710:CCT:C	donor_gain	1.0000
11:61765711:CT:C	donor_gain	1.0000
11:61765711:CTGT:C	donor_loss	1.0000
11:61765712:TGTG:T	donor_loss	1.0000
11:61765713:G:GG	donor_gain	1.0000
11:61765714:T:A	donor_loss	1.0000
11:61765715:G:GC	donor_loss	1.0000
11:61770518:GGAGC:G	donor_gain	1.0000
11:61770519:GAGC:G	donor_gain	1.0000
11:61770521:GC:G	donor_gain	1.0000
11:61770521:GCTGA:G	donor_gain	1.0000
11:61770522:C:G	donor_gain	1.0000
11:61770524:GA:G	donor_gain	1.0000
11:61770526:G:GG	donor_gain	1.0000
11:61770530:GAC:G	donor_gain	1.0000
11:61771827:AG:A	acceptor_gain	1.0000
11:61771828:GG:G	acceptor_gain	1.0000
11:61771828:GGCC:G	acceptor_gain	1.0000
11:61771948:GAGCT:G	donor_gain	1.0000
11:61771950:GCT:G	donor_gain	1.0000

AlphaMissense

7511 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:61771889:T:A	I351N	1.000
11:61771894:T:A	W353R	1.000
11:61771894:T:C	W353R	1.000
11:61771895:G:C	W353S	1.000
11:61771896:G:C	W353C	1.000
11:61771896:G:T	W353C	1.000
11:61771918:T:A	W361R	1.000
11:61771918:T:C	W361R	1.000
11:61773980:T:G	Y377D	1.000
11:61773987:T:A	V379E	1.000
11:61773993:C:A	A381E	1.000
11:61773995:G:C	D382H	1.000
11:61773996:A:T	D382V	1.000
11:61773998:A:C	K383Q	1.000
11:61773998:A:G	K383E	1.000
11:61773999:A:C	K383T	1.000
11:61773999:A:T	K383M	1.000
11:61774000:G:C	K383N	1.000
11:61774000:G:T	K383N	1.000
11:61774001:G:A	G384S	1.000
11:61774001:G:C	G384R	1.000
11:61774001:G:T	G384C	1.000
11:61774002:G:A	G384D	1.000
11:61774002:G:T	G384V	1.000
11:61774004:T:C	F385L	1.000
11:61774005:T:C	F385S	1.000
11:61774005:T:G	F385C	1.000
11:61774006:C:A	F385L	1.000
11:61774006:C:G	F385L	1.000
11:61774010:T:C	F387L	1.000

dbSNP variants (sampled 300 via entrez): RS1000172133 (11:61763613 C>T), RS1000224871 (11:61764357 A>G), RS1000238769 (11:61760489 G>T), RS1000401284 (11:61776361 G>A,C,T), RS1000478188 (11:61775184 G>A), RS1000557222 (11:61763386 C>T), RS1000636503 (11:61782241 C>A,T), RS1000736421 (11:61774877 C>T), RS1000754972 (11:61789019 T>A,C), RS1000955626 (11:61754068 G>A), RS1000987448 (11:61782644 G>A,T), RS1001069074 (11:61760191 A>C), RS1001207069 (11:61759586 C>T), RS1001280833 (11:61759913 T>C), RS1001445514 (11:61764130 G>C,T)

Disease associations

OMIM: gene MIM:608329 | disease phenotypes: MIM:618113, MIM:618280, MIM:600165, MIM:142340, MIM:236750

GenCC curated gene-disease

Disease	Classification	Inheritance
cardiac-urogenital syndrome	Strong	Autosomal dominant
hyperopia	Strong	Autosomal dominant
encephalitis/encephalopathy, mild, with reversible myelin vacuolization	Limited	Autosomal dominant

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
cardiac-urogenital syndrome	Definitive	AD

Mondo (12): encephalitis/encephalopathy, mild, with reversible myelin vacuolization (MONDO:0020853), cardiac-urogenital syndrome (MONDO:0032653), disorder of sexual differentiation (MONDO:0002145), scimitar syndrome (MONDO:0015987), prostate cancer (MONDO:0008315), neurodevelopmental disorder (MONDO:0700092), nanophthalmos 1 (MONDO:0010836), congenital diaphragmatic hernia (MONDO:0005711), urogenital tract malformation (MONDO:0019356), non-immune hydrops fetalis (MONDO:0009369), dextrocardia (MONDO:0015661), hyperopia (MONDO:0004891)

Orphanet (9): Cardiac-urogenital syndrome (Orphanet:647811), Difference of sex development (Orphanet:90771), Scimitar syndrome (Orphanet:185), Familial prostate cancer (Orphanet:1331), Nanophthalmos (Orphanet:35612), Congenital diaphragmatic hernia (Orphanet:2140), Urogenital tract malformation (Orphanet:83001), Non-immune hydrops fetalis (Orphanet:363999), Dextrocardia (Orphanet:1666)

HPO phenotypes

44 total (30 of 44 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000028	Cryptorchidism
HP:0000048	Bifid scrotum
HP:0000054	Micropenis
HP:0000062	Ambiguous genitalia
HP:0000105	Enlarged kidney
HP:0000151	Aplasia of the uterus
HP:0000431	Wide nasal bridge
HP:0000776	Congenital diaphragmatic hernia
HP:0000808	Penoscrotal hypospadias
HP:0001249	Intellectual disability
HP:0001250	Seizure
HP:0001270	Motor delay
HP:0001629	Ventricular septal defect
HP:0001631	Atrial septal defect
HP:0001636	Tetralogy of Fallot
HP:0001643	Patent ductus arteriosus
HP:0001649	Tachycardia
HP:0001651	Dextrocardia
HP:0001698	Pericardial effusion
HP:0001747	Accessory spleen
HP:0002089	Pulmonary hypoplasia
HP:0002566	Intestinal malrotation
HP:0002779	Tracheomalacia
HP:0002780	Bronchomalacia
HP:0003010	Prolonged bleeding time
HP:0003621	Juvenile onset
HP:0004383	Hypoplastic left ventricle
HP:0004691	2-3 toe syndactyly
HP:0006846	Acute encephalopathy

GWAS associations

142 associations (top):

Study	Trait	p-value
GCST001178_6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid)	6.000000e-58
GCST001179_1	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid)	1.000000e-151
GCST001180_3	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid)	1.000000e-63
GCST001725_11	Inflammatory bowel disease	2.000000e-15
GCST001834_5	Oleic acid (18:1n-9) levels	2.000000e-32
GCST001841_1	Palmitoleic acid (16:1n-7) levels	7.000000e-13
GCST002444_5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid)	5.000000e-168
GCST002446_1	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid)	4.000000e-274
GCST002446_7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid)	3.000000e-21
GCST002448_6	Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid)	4.000000e-140
GCST002449_6	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid)	0.000000e+00
GCST002449_8	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid)	7.000000e-147
GCST002450_8	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid)	2.000000e-72
GCST002454_8	Colorectal cancer	9.000000e-21
GCST002457_3	P wave duration	3.000000e-08
GCST002712_12	Red blood cell fatty acid levels	2.000000e-12
GCST002712_2	Red blood cell fatty acid levels	8.000000e-90
GCST002712_3	Red blood cell fatty acid levels	1.000000e-09
GCST002712_4	Red blood cell fatty acid levels	3.000000e-305
GCST002712_7	Red blood cell fatty acid levels	3.000000e-19
GCST002712_8	Red blood cell fatty acid levels	2.000000e-10
GCST002712_9	Red blood cell fatty acid levels	6.000000e-43
GCST003818_34	Resting heart rate	2.000000e-30
GCST004132_88	Crohn’s disease	9.000000e-07
GCST004139_2	Bipolar disorder	1.000000e-10
GCST004139_22	Bipolar disorder	6.000000e-09
GCST004571_28	Iron status biomarkers (total iron binding capacity)	5.000000e-08
GCST004572_9	Iron status biomarkers (transferrin saturation)	5.000000e-08
GCST004601_157	Red blood cell count	4.000000e-21
GCST004602_195	Mean corpuscular volume	7.000000e-11

EFO canonical traits (31, from GWAS)

EFO ID	Trait name
EFO:0007760	eicosapentaenoic acid measurement
EFO:0006809	docosapentaenoic acid measurement
EFO:0007759	alpha-linolenic acid measurement
EFO:0005680	omega-6 polyunsaturated fatty acid measurement
EFO:0005094	P wave duration
EFO:0006810	oleic acid measurement
EFO:0006808	arachidonic acid measurement
EFO:0006807	linoleic acid measurement
EFO:0006811	linolenic acid measurement
EFO:0006334	total iron binding capacity
EFO:0004305	erythrocyte count
EFO:0004348	hematocrit
EFO:0004509	hemoglobin measurement
EFO:0007986	reticulocyte count
EFO:0007764	delta-5 desaturase measurement
EFO:0009131	response to polyunsaturated fatty acid supplementation
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0004530	triglyceride measurement
EFO:0009594	irritability measurement
EFO:0009270	heel bone mineral density
EFO:0003924	hair color
EFO:1002011	adult onset asthma
EFO:0009963	bipolar I disorder
EFO:0004469	HOMA-B
EFO:0010382	phosphatidylcholine 36:4 measurement
EFO:0010118	sphingomyelin measurement
EFO:0005059	acylcarnitine measurement
EFO:0006944	systolic blood pressure change measurement
EFO:0010119	omega-3 polyunsaturated fatty acid measurement
EFO:0004346	neuroimaging measurement

MeSH disease descriptors (8)

Descriptor	Name	Tree numbers
D003914	Dextrocardia	C14.240.400.280; C14.280.400.280; C16.131.240.400.280; C16.131.810.250
D012734	Disorders of Sex Development	C12.050.351.875.253; C12.200.706.316; C12.800.316; C16.131.939.316; C19.391.119
D065630	Hernias, Diaphragmatic, Congenital	C16.131.433; C23.300.707.960.500.116
D006956	Hyperopia	C11.744.479
D065886	Neurodevelopmental Disorders	F03.625
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750
D012587	Scimitar Syndrome	C08.381.844; C08.695.815; C14.240.850.968; C14.907.780; C16.131.240.850.937; C16.131.740.815
C563983	Nanophthalmos 1 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

30 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Acetaminophen	decreases expression	2
Benzo(a)pyrene	increases methylation, increases expression	2
Cisplatin	increases expression, affects response to substance, affects cotreatment	2
Aflatoxin B1	decreases methylation, increases methylation	2
FR900359	decreases phosphorylation	1
dicrotophos	increases expression	1
methyleugenol	increases expression	1
bisphenol A	increases expression	1
cobaltous chloride	decreases expression	1
butyraldehyde	decreases expression	1
benzo(e)pyrene	increases methylation	1
2-palmitoylglycerol	increases expression	1
abrine	decreases expression	1
jinfukang	affects cotreatment, increases expression	1
(+)-JQ1 compound	decreases expression	1
Capecitabine	increases response to substance	1
Sunitinib	decreases expression	1
Arsenic	affects methylation	1
Vehicle Emissions	increases abundance, increases expression	1
Caffeine	increases phosphorylation	1
Lead	affects methylation	1
Methapyrilene	increases methylation	1
Niclosamide	increases expression	1
Silicon Dioxide	decreases expression	1
Smoke	decreases expression	1
Tobacco Smoke Pollution	affects expression	1
Triclosan	increases expression	1
Antirheumatic Agents	increases expression	1
Vitamin K 3	affects expression	1
Particulate Matter	increases abundance, increases expression	1

Clinical trials (associated diseases)

422 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00347204	PHASE4	COMPLETED	Comparison of Acular LS Versus Nevanac for Pain Control in Eyes Undergoing PRK
NCT00455455	PHASE4	COMPLETED	Corneal and Conjunctival Sensitivity and Staining Study
NCT00937105	PHASE4	COMPLETED	Daily Wear Corneal Infiltrative Event Study
NCT01387360	PHASE4	COMPLETED	Presbyopic Supracor Treatment for Near Myopic/Hyperopic Pseudophakic Eyes
NCT01977807	PHASE4	UNKNOWN	A Prospective Safety and Effectiveness Study of the 500 Hz Technolas Perfect Vision Excimer Laser in Asian Eyes Using LASIK
NCT02071576	PHASE4	UNKNOWN	A Prospective Safety and Effectiveness Study of the 500 Hz Technolas Perfect Vision Excimer Laser Using LASIK
NCT02112968	PHASE4	UNKNOWN	A Prospective Safety and Effectiveness Study of a New High Repetition Rate Excimer Laser Using LASIK for the Correction of Ammetropia and Presbyopia
NCT03881670	PHASE4	COMPLETED	On-Eye Optical Quality of Lotrafilcon B Lenses Over 12 Hours
NCT04208750	PHASE4	COMPLETED	Clinical Investigation of the Vision-R800 Device.
NCT04283331	PHASE4	UNKNOWN	Anesthetic Impregnated Bandage Soft Contact Lens (BSCL) in Pain Management After Photorefractive Keratectomy (PRK)
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart